International Journal of Biomedical Investigation

journal homepage: https://ijbi.edwiserinternational.com

Original Article

Toward a Smart Regulatory Ecosystem: The Convergence of Artificial Intelligence, Analytical Chemistry and Global Drug Approval Pathways

M. Megala[1,*], T. Saraswathy[1], R. Priya Dharsini[1], M. Sathish[1], P.G. Sunitha[1] and R. Devi Damayanthi[2]

[1]Department of Pharmaceutical Chemistry, College of Pharmacy, Madras Medical College, Affiliated to The Tamil Nadu Dr. M.G.R. Medical University, Chennai, Tamil Nadu, India
[2]Department of Pharmaceutics, College of Pharmacy, Madras Medical College, Affiliated to The Tamil Nadu Dr. M.G.R. Medical University, Chennai, Tamil Nadu, India

ARTICLE INFO

Received 20 August 2025
Revised 15 September 2025
Available Online 20 September 2025

Keywords:
Regulatory Affairs
Pharmacovigilance
Artificial Intelligence
Predictive Toxicology
Stability Indicating Methods
Adavanced pharmaceutical analytics

ABSTRACT

Background: Regulatory Affairs (RA) has long served as the backbone of the Pharmaceutical Industry ensuring compliance with safety, efficacy and quality standards through dossier preparation, drug approvals and post marketing surveillance. However, increasing submission complexity, large regulatory datasets and growing demand for rapid approvals pose major challenges. At the same time, Artificial Intelligence (AI) is emerging as a transformative force across Pharmaceutical Sciences with applications in drug discovery, predictive toxicology, Pharmacovigilance and analytical method development. Its integration into regulatory affairs practice marks a paradigm shift from documentation based processes to predictive, data driven models.

Objective: This review explores the convergence of AI, advanced pharmaceutical analytics and regulatory affairs practice. It highlights current applications, benefits and limitations while outlining future opportunities to advance towards a smart, technology enabled regulatory ecosystem.

Methods: A narrative review of peer reviewed literature, regulatory guidelines and industry reports was conducted, focusing on AI applications in stability indicating method development, degradation profiling, In-silico toxicology, dossier preparation, pharmacovigilance, Chemistry Manufacturing and Controls (CMC) and regulatory intelligence.

Results: AI technologies such as machine learning, deep learning, natural language processing and generative AI are reshaping modern Pharmaceutical Analytics by enabling predictive degradation modeling, optimizing UHPLC/UPLC methods and supporting sustainable green chemistry initiatives. Within regulatory affairs practice, AI facilitates eCTD (Electronic Common Technical Document) dossier preparation, enhances pharmacovigilance through automated signal detection and strengthens global regulatory intelligence. These innovations accelerate approvals, improve data quality, reduce costs and enhance patient safety. However, challenges remain, including regulatory acceptance of AI driven outcomes, ensuring algorithm transparency, maintaining data integrity and the absence of globally harmonized standards across regulatory agencies.

Conclusion: AI driven regulatory affairs practice offers the potential to shift drug development and approval towards proactive, real- time and patient centered decision making. Future directions include regulatory sandboxes, incorporation of AI into ICH guidelines, adoption of digital twins,

blockchain and personalized medicine approvals. A balanced approach embracing innovation while addressing ethical, legal and global challenges will be critical to fully realize AI's potential in reshaping Pharmaceutical Innovation.

Introduction

Traditional Role of Regulatory Affairs in Pharma: Regulatory Affairs (RA) has historically served as the backbone of the Pharmaceutical Industry, ensuring that drug development, manufacturing and marketing processes comply with both National and International standards. Acting as the central link between pharmaceutical companies and regulatory bodies, RA professionals oversee dossier preparation, approval procedures, compliance auditing and Post Marketing Surveillance to maintain product safety, efficacy and quality [1-10]. Despite its robustness, this framework faces challenges including the rising complexity of submissions the large volume of regulatory data and the growing demand for rapid drug approvals in a competitive global market [7].

Rise of Artificial Intelligence (AI) in Healthcare and Pharma: In recent years, Artificial Intelligence (AI) has emerged as a transformative force across Healthcare and Pharmaceutical Sciences. Technologies such as Machine Learning (ML), Natural Language Processing (NLP) and deep learning have been applied to Drug Discovery, Pharmacovigilance, Formulation design and Quality control with significant potential to reduce timelines and costs [3,4,6,9,11]. In Healthcare, AI has redefined diagnostics, predictive modelling and personalized medicine [3,11]. Within pharmacy, it has advanced stability indicating method development, degradation product profiling and predictive toxicology, thereby expanding its role in both analytical and regulatory domains [4,9,12].

*Corresponding author: M. Megala, Department of Pharmaceutical Chemistry, College of Pharmacy, Madras Medical College, Affiliated to The Tamil Nadu Dr. M.G.R Medical University, Chennai-600 003, Tamil Nadu, India.

https://doi.org/10.31531/2581-4745.1000170

Need for Integrating Adavanced Pharmaceutical Analytics, AI and Regulatory affairs practices: The convergence of Adanced pharmaceutical analytics, AI and Regulatory affairs practice is increasingly necessary to meet modern industry demands. AI driven tools enable optimization of analytical methods, prediction of impurity formation, automation of dossier compilation and enhanced Pharmacovigilance monitoring. This integration not only accelerates submissions but also strengthens compliance and scientific rigor [1,8]. Such advancements signal a paradigm shift from documentation driven processes toward data centric, predictive and intelligent regulatory affairs practice.

Objective of the Review: This review critically examines the intersection of Regulatory Affairs, Artificial Intelligence and Advanced pharmaceutical analytics. It highlights current applications, opportunities, challenges and future perspectives with particular focus on how AI can support drug development, safety monitoring and compliance. The ultimate objective is to provide a comprehensive understanding of how AI enabled regulatory affairs practice can reshape the future of pharmaceutical innovation. Figure 1 illustrates the conceptual framework of this review, highlighting the convergence of artificial intelligence, pharmaceutical analytics and regulatory affairs practice in shaping modern drug approval pathways.

AI in the Pharmaceutical Domain

AI Technologies Relevant to Pharma: Artificial Intelligence (AI) encompasses a broad spectrum of technologies such as Machine Learning (ML), Deep Learning (DL), Natural Language Processing (NLP), predictive modeling and generative AI which are increasingly transforming the pharmaceutical affairs practice. These advanced tools allow the analysis of complex datasets, identification of hidden patterns and prediction of outcomes that were previously unattainable through conventional computational approaches [13-20].



Figure 1: Conceptual Framework of AI Enabled Regulatory affairs practice.

- ML and DL models serve as the foundation for predictive applications including drug target interactions, toxicity screening and pharmacokinetic predictions [13,17].
- NLP facilitates mining of unstructured data from regulatory submissions and clinical trial documents, enhancing regulatory affairs practice and decision making.[16]
- Generative AI is a powerful tool in Drug Discovery, enabling Retrosynthetic planning, De novo Molecular Design and Chemical library expansion [18,19].

Together, these technologies are reshaping the pharmaceutical innovation pipeline by enabling data driven, faster and more efficient research.

Applications in Advanced pharmaceutical analytics

Drug Design and Molecular Modelling: AI driven approaches in drug design integrate Structure Activity Relationships (SARs), Molecular Docking and Computational biology to predict promising lead candidates with improved binding affinities. Studies show that deep learning and generative models can outperform traditional QSAR methods by leveraging big data, resulting in faster identification of novel scaffolds [13,20-23]. Generative AI has also been applied to design drug like molecules with tailored Pharmacological properties, thereby accelerating early discovery [16,18].



Figure 2: Applications of AI in Adanced pharmaceutical analytics.

ADMET Prediction: Prediction of Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) is a cornerstone of Advanced pharmaceutical analytics. AI platforms such as ADMET AI employ ML algorithms to deliver large scale predictions of ADMET properties across chemical libraries, reducing attrition rates in drug development [13,17]. By integrating cheminformatics and bioinformatics data, AI systems enhance the accuracy of predicting Drug- Drug interactions, metabolism pathways and potential safety concerns [23].

Degradation Product Profiling: Drug stability is critical for regulatory compliance and AI has shown increasing utility in predictive modelling of degradation behaviour. By simulating stress conditions and degradation kinetics, AI systems can anticipate the formation of impurities with degradation products without extensive experimental work [15]. Such predictive insights are particularly valuable for stability indicating method development aligned with ICH guidelines.

Analytical Method Development and Validation: In the domain of Pharmaceutical Analysis AI is being applied to optimize chromatographic techniques such as HPLC and UHPLC. Predictive algorithms can assist in selecting optimal mobile phase composition, flow rates and columns, leading to efficient method development with fewer experimental trials [21]. AI also supports method validation by automating assessments of parameters such as precision, accuracy and robustness leading to aligning analytical practices more closely with regulatory expectations. The diverse applications of AI in Advanced pharmaceutical analytics, ranging from drug design to stability assessment are summarized in Figure 2 and Table 1.

Table 1: AI Tools in Adanced pharmaceutical analytics.

Domain	AI Tools/Models	Application Example
Drug Design	Generative AI, DL	Scaffold design, virtual screening [13,20,23]
ADMET	ADMET-AI, ML	Large scale prediction of Properties [17,23]
Stability	Predictive ML, KNIME based tools	Forecast degradation pathways [15]
Analytical Method Development	AI + UHPLC/UPLC	Mobile phase optimization [21]

Case Studies in Pharma R&D

Several practical examples demonstrate the growing role of AI in Pharmaceutical Research and development. For instance, ML based ADMET models have been used to efficiently screen large chemical libraries, identifying high potential leads while saving time and resources [17]. Generative AI has been employed by both academia and industry to design novel antibiotic and anticancer candidates, reflecting its disruptive potential [20,21]. AI assisted stability modelling has already been incorporated into regulatory submissions to predict shelf life and support accelerated approvals [15,22]. Moreover, the integration of computational biology with AI has enabled In-silico drug design strategies that complement traditional medicinal chemistry, creating a hybrid discovery model [20,23].

Overall, AI is reshaping Advanced pharmaceutical analytics by advancing Drug Design, ADMET prediction, stability assessment and Analytical method development. These applications not only accelerate innovation but also improve compliance with regulatory frameworks, driving the transition toward a data centric and predictive pharmaceutical affairs practices ecosystem.

Regulatory Affairs: Current Landscape

Regulatory affairs serve as the backbone of modern drug discovery and development, ensuring that medicines entering the market are safe, efficacious and of assured quality. The discipline acts as the critical interface between pharmaceutical innovation and public health by translating laboratory findings into products that comply with global regulatory requirements [24-27].

Role of Regulatory Affairs in Drug Discovery & Development: The contribution of regulatory affairs extends throughout the drug lifecycle from Preclinical research, clinical trials and dossier preparation to post marketing surveillance. Regulatory professionals ensure that the generated data on Chemistry Manufacturing and Controls (CMC) support the identity, strength, quality, purity and stability of pharmaceutical products [28,29]. This systematic

oversight reduces risks associated with unsafe medicines and accelerates access to novel therapies.

Global Regulatory Frameworks: Drug approvals are governed by stringent regulatory frameworks across major agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and Central Drugs Standard Control Organization (CDSCO) in India. Additionally, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) plays a pivotal role in harmonizing global standards, reducing redundancy in submissions and facilitating simultaneous approvals in multiple regions [27-32]. These frameworks emphasize safety, efficacy and quality as the three pillars of drug approval.

Quality, Safety and Efficacy: The cornerstone of all regulatory submissions is the demonstration of quality, safety and efficacy. The CMC section ensures the drug substance and product meet required specifications, while toxicological and clinical data validate safety and therapeutic benefit [29]. Regulators also evaluate pharmacovigilance systems to monitor risks after market entry which is particularly critical in the era of complex biologics and biosimilars [30].

Challenges in Current Systems: Despite progress regulatory systems face significant challenges. The exponential growth of clinical and non-clinical data creates data overload, complicating review timelines and increasing the probability of errors [31]. Manual dossier reviews are resource intensive, leading to delays in approvals and rising costs for sponsors. Moreover, the growing complexity of submissions driven by biosimilars, advanced therapies and globalized trials places additional strain on regulatory authorities [26,32]. In this context AI and big data analytics are increasingly recognized as transformative tools to streamline decision making, automate data verification and enhance regulatory intelligence [26,31].

Intersection of AI and Regulatory affairs practice

The integration of Artificial Intelligence (AI) into Regulatory affairs practice is reshaping how pharmaceutical Companies and regulatory authorities approach submissions, Pharmacovigilance, Chemistry Manufacturing Controls (CMC) and Global intelligence.

AI for Regulatory Submissions: The preparation of Regulatory Dossiers, particularly electronic Common Technical Document (eCTD) submissions has traditionally been resource intensive and time consuming. AI and automation are increasingly applied to streamline dossier compilation, metadata tagging, document version control and life cycle management thereby improving compliance and reducing human error [34-40]. By embedding data analytics, regulatory teams can anticipate queries from agencies and ensure timely harmonized global submissions.

AI for Pharmacovigilance: Pharmacovigilance remains a cornerstone of regulatory affairs practice with AI offering novel methods for adverse drug reaction (ADR) detection, signal prioritization and real world evidence mining. AI models are capable of handling large, heterogeneous datasets including spontaneous reports, social media and electronic health records to detect patterns that may not be readily apparent through conventional methods [33,36,38]. In addition, machine learning approaches enable more accurate prediction of drug-drug interactions and facilitate proactive risk minimization strategies, improving patient safety [36,38].

AI in Chemistry Manufacturing and Controls (CMC): AI has begun to transform CMC activities by optimizing stability studies, impurity profiling and analytical method development. For instance, predictive algorithms can estimate product stability under different environmental conditions, minimizing the need for extended real time studies [32]. Machine learning further assists in impurity tracking and analytical method optimization, offering better sensitivity, reproducibility and robustness compared to conventional approaches. These advances support faster regulatory compliance while ensuring drug quality and safety throughout the product life cycle [40-43].

Table 2: AI Applications Across Regulatory affairs practice.

Area of Application	AI Contribution	Regulatory Impact
Dossier Preparation	NLP, Automation	Faster eCTD submissions, reduced errors [34,39,40]
Pharmacovigilance	ML, Big Data	Better ADR detection, real time safety [33,36,38]
CMC & Stability Studies	Predictive ML	Faster impurity / Stability predictions [32]
Toxicology	QSAR, DL models	Reduced animal testing, predictive safety [42]

AI for Regulatory Intelligence: The dynamic nature of pharmaceutical regulations across global markets creates a challenge for companies pursuing simultaneous approvals. AI driven regulatory intelligence tools enable continuous monitoring of evolving guidelines, gap analysis and automated mapping of regional variations [35,37]. By facilitating real time surveillance of international regulatory frameworks, AI fosters regulatory harmonization and reduces duplication of effort for multinational submissions. Importantly, embedding ethical frameworks within these systems ensures transparency, accountability and trustworthiness in regulatory decision making [35]. Table 2 provides an overview of AI applications across regulatory affairs practice, illustrating their impact on dossier preparation, pharmacovigilance, CMC and regulatory intelligence.

Collectively, the intersection of AI with regulatory affairs practice enables a paradigm shift toward more proactive, data driven and harmonized regulatory practices. This transformation has the potential to not only expedite patient access to innovative therapies but also maintain the highest standards of safety, efficacy and quality.

Advanced pharmaceutical analytics Perspective

AI driven Stability Indicating Method Development: The development of Stability Indicating Methods (SIMs) has traditionally relied on trial and error experimentation which can be time consuming and resource intensive. Artificial intelligence (AI) has emerged as a transformative tool in Advanced pharmaceutical analytics by enabling predictive modelling for chromatographic behaviour and degradation pathways. AI driven approaches allow rapid optimization of UHPLC/UPLC methods by integrating data on solvent systems, pH, stationary phase characteristics and molecular descriptors of analytes thereby reducing the experimental workload. Machine learning (ML) algorithms have also been successfully applied to predict chromatographic retention times and optimize separation conditions, supporting the regulatory requirement for stability indicating assays [41]. Such integration ensures robust analytical methods with enhanced reproducibility and regulatory acceptability.

AI in Forced Degradation Prediction and Degradant Profiling: Forced degradation studies are a critical component of regulatory submissions, required to demonstrate the specificity and stability indicating nature of analytical methods. AI can predict forced degradation outcomes by simulating stress conditions such as hydrolysis, oxidation, photolysis and thermal degradation. Computational models trained on large datasets of known degradants allow prediction of possible breakdown products even before laboratory experimentation [44]. Additionally, AI driven spectral interpretation tools can accelerate degradant profiling by deconvoluting LC-MS/MS or NMR data, reducing ambiguity in structural elucidation. This predictive ability enhances regulatory confidence while minimizing the risk of overlooking toxic or reactive degradation products [45-48].

Predictive Toxicology and In-silico Regulatory Submissions: Toxicological profiling of Active Pharmaceutical Ingredients (APIs) and their degradation products is a key element of regulatory review. Traditionally, this requires extensive in-vitro and in-vivo testing. however, AI based predictive toxicology provides an efficient and ethical alternative. Quantitative structure activity relationship (QSAR) models, deep learning and ensemble classifiers are increasingly used to forecast endpoints such as mutagenicity, hepatotoxicity and cardiotoxicity [42-47]. In-silico toxicology models, when developed under FAIR (Findable, Accessible, Interoperable, Reusable) principles are now recognized by regulatory authorities as supportive evidence in submissions [42]. This shift enhances the speed of pharmaceutical development while aligning with global initiatives for reduced animal testing.

Role in Green Chemistry and Sustainable Regulatory Compliance: Green chemistry principles emphasize waste minimization, safer solvents and energy efficient processes. AI supports these goals by designing synthetic pathways that minimize hazardous intermediates and optimize reagent selection [41-49]. In analytical sciences, AI helps select environmentally friendly mobile phases, optimize sample preparation and predict energy efficient chromatographic conditions. This approach not only improves sustainability but also facilitates compliance with emerging regulatory frameworks that encourage greener practices in pharmaceutical manufacturing and analysis. AI thus acts as both a compliance enabler and a driver of eco-innovation [44,49].

Integration of AI with UHPLC/UPLC and Spectral Techniques for Regulatory Ready Data: The integration of AI with advanced analytical techniques such as UHPLC/UPLC and mass spectrometry offers a powerful route to generating regulatory ready data. AI algorithms can automatically identify chromatographic peaks, predict co-elution and deconvolute complex spectral data [15,48]. This integration enables real time quality control and automated reporting systems aligned with regulatory expectations for data integrity and reproducibility. Furthermore, AI enabled platforms can

harmonize multi-omics datasets with chromatographic profiles, strengthening mechanistic understanding of drug stability and toxicity [45]. Such advancements ensure that data generated in advanced pharmaceutical analytics not only meet but exceed the standards required for regulatory approval.

Opportunities and Benefits

Accelerated approvals: Artificial Intelligence (AI) has become a key enabler in expediting regulatory submissions and drug approvals. By integrating predictive models and real world data, AI facilitates rapid evidence generation that supports accelerated approval pathways. This has been demonstrated in regulatory affairs practice where AI driven data integration reduces the time between drug discovery and patient access [50]. Such systems not only complement the FDA's accelerated approval initiatives but also strengthen the scientific rigor of conditional approvals.

Enhanced data quality and reproducibility: Reproducibility is a cornerstone of regulatory acceptance. AI and machine learning tools contribute to standardizing workflows, detecting anomalies and ensuring reproducibility of analytical and clinical datasets [51]. Trustworthy AI frameworks further enhance scientific reproducibility by reducing biases and enabling transparent model interpretation [52-58]. This is critical in Advanced pharmaceutical analytics where reproducible results form the basis for validated methods and regulatory compliance.

Reduced regulatory burden: The integration of AI into regulatory affairs reduces manual workload in compliance monitoring and reporting. Similar to how AI is transforming regulatory reporting in financial systems [55], pharmaceutical applications can leverage automated dashboards and intelligent documentation tools to simplify submission preparation. This minimizes administrative burden and ensures faster communication between regulators and industry [56].

Better patient safety monitoring: Patient safety remains at the core of pharmaceutical regulation. AI powered Pharmacovigilance systems enable real time monitoring of adverse drug reactions, automated signal detection and predictive risk assessment [54]. These intelligent systems support regulatory authorities in maintaining proactive safety surveillance thereby protecting patients and strengthening regulatory trust.

Cost effectiveness in Advanced pharmaceutical analytics R&D: AI driven innovations are redefining cost structures in drug discovery and advanced pharmaceutical analytics. From predictive toxicology to AI assisted synthesis design, machine learning models reduce the need for repetitive experimental trials [52-60]. This accelerates method development, enhances supply chain efficiency and optimizes resources, ultimately leading to lower R&D costs while maintaining regulatory compliance [53]. A balanced comparison of opportunities and challenges in adopting AI for regulatory affairs practice is presented in Table 3.

Table 3: Opportunities *vs* Challenges.

Opportunities	Benefits	Challenges
Accelerated approvals	Faster access to medicines	Algorithm transparency [32,50]
Enhanced data quality	More reproducible methods	Lack of global harmonization [40,57]
Cost reduction	Lower R & D costs	AI validation standards, missing [32,52]
Patient safety	Real time Pharmacovigilance	Ethical legal issues [35,54]

Challenges and Limitations

Despite the transformative potential of Artificial Intelligence (AI) in pharmaceutical affairs practices and Regulatory Affairs, several barriers continue to limit its seamless integration into drug development and quality control processes.

Regulatory acceptance of AI driven results: The foremost challenge lies in regulatory recognition of AI generated outcomes. Agencies such as the US FDA and EMA demand reproducibility, robustness and traceability in data used for submissions. However, AI algorithms especially those based on deep learning often operate as "black boxes," making it difficult for regulators to validate the decision making process. This raises concerns regarding the reliability of AI assisted stability studies, impurity profiling and predictive toxicology [34,37].

Data integrity, transparency and explainability issues: Advanced pharmaceutical analytics relies on high quality experimental and computational data for

regulatory submissions. AI systems trained on incomplete, biased or non-standardized datasets risk compromising data integrity. Moreover, the lack of explainability in AI predictions complicates their adoption in areas such as forced degradation modelling, spectral interpretation and impurity characterization. Regulators increasingly emphasize the need for explainable AI frameworks to ensure transparency in compliance reports [33,36,38].

Ethical and legal concerns: Ethical challenges include safeguarding patient data used in clinical pharmacology models and preventing algorithmic bias that could misrepresent chemical safety profiles. From a legal perspective, uncertainties remain regarding liability if AI based predictions result in erroneous regulatory submissions or overlooked toxicological risks. These concerns necessitate clear guidelines on accountability and compliance [35,37].

Variability in global regulatory adoption: While some regions (e.g., the United States, Europe and Japan) are actively exploring AI enabled regulatory affairs practice, others lag due to infrastructural, economic or policy limitations. This variability creates inconsistencies in global Advanced pharmaceutical analytics practices, particularly in areas like stability indicating UHPLC/UPLC methods or AI driven impurity prediction. Such divergence complicates harmonization efforts under ICH guidelines [37,40].

Validation and standardization of AI algorithms for regulatory use: Unlike conventional analytical methods that follow well-defined ICH Q2(R1) validation guidelines, AI tools lack universal standards for verification, validation and lifecycle management. Establishing benchmarks for algorithm accuracy, reproducibility and robustness in advanced pharmaceutical analytics applications such as chromatographic optimization or degradation pathway modelling is critical for regulatory acceptance [32,34,39].

Future Directions

AI Regulatory Sandboxes and Pilot Programs: AI regulatory sandboxes and pilot programs are anticipated to play a pivotal role in ensuring the safe and effective adoption of AI in Pharmaceutical Regulation. These frameworks provide a controlled environment where regulators and industry stakeholders can test AI driven tools, ensuring transparency, explainability and compliance before their large-scale integration into regulatory workflows [61,62].

Integration of AI into ICH Guidelines: Embedding AI into International Council for Harmonisation (ICH) guidelines represents a major step forward in regulatory affairs practice. Establishing harmonized standards for validation, data integrity and quality control of AI applications will support global acceptance of AI enabled processes [63]. Such integration would streamline international collaboration, minimize redundancy in submissions and potentially accelerate drug approval timelines across multiple regions.

Role of Digital Twins, Blockchain, and Big Data: The convergence of digital twins, blockchain and big data analytics is increasingly viewed as transformative for regulatory affairs practice. Digital twins allow virtual simulations of patient outcomes or drug degradation pathways, providing predictive insights for regulatory decisions. Blockchain technology ensures secure, transparent and tamper proof regulatory records, while big data analytics enhances Pharmacovigilance, real world evidence generation and risk-benefit assessments, supporting more informed decision making [64–66].

Personalized Medicine Approvals Powered by AI: AI powered personalized medicine approvals are emerging as a priority for future regulatory frameworks. Algorithms capable of analyzing genomic, proteomic and clinical datasets can guide individualized drug approval processes. This approach shifts regulation from traditional population based evaluation models toward precision driven, adaptive pathways tailored to patient specific needs, aligning with the era of personalized medicine [67,68].

Vision of a "Smart Regulatory Ecosystem" for Pharma: The ultimate vision is the establishment of a smart regulatory ecosystem, where AI, automation and advanced digital tools are seamlessly integrated into Pharmaceutical Regulation. Such an ecosystem would enable faster and more transparent reviews, ensure sustainable compliance and deliver patient centered outcomes. By embracing these innovations, regulatory affairs practice can align with the next generation of therapeutic and technological advancements [69].

Beyond AI: The Horizon of AGI and ASI in Regulation: Looking further ahead the potential evolution toward Artificial General Intelligence (AGI) and Artificial Superintelligence (ASI) presents a transformative horizon for pharmaceutical regulation. While still theoretical, AGI could autonomously integrate scientific, clinical and regulatory datasets to provide holistic decision making for drug evaluation. ASI with intelligence surpassing human capabilities, could revolutionize predictive toxicology, global harmonization and patient centric approvals by modelling unprecedentedly complex variables. Although their application in regulatory affairs practice remains distant, acknowledging AGI and ASI highlights

the trajectory of innovation and underscores the need for proactive ethical, legal and governance frameworks to prepare for such advancements [70,71].

Conclusion

Artificial Intelligence (AI) has emerged as a disruptive force in pharmaceutical analytics and regulatory affairs practice driving a transition from retrospective, documentation driven approaches to proactive, predictive and data centric frameworks. By integrating machine learning, deep learning, natural language processing and generative models, AI enables predictive degradation modelling, accelerates analytical method development, optimizes UHPLC/UPLC workflows and supports green chemistry initiatives, thereby reducing attrition and improving regulatory readiness [72-74]. Within regulatory affairs practice, AI strengthens dossier preparation, enhances pharmacovigilance through automated signal detection and augments regulatory intelligence, leading to faster approvals, improved reproducibility and greater patient safety [72].

Despite these transformative advantages critical barriers remain. Regulatory acceptance of AI- driven outputs is still evolving with agencies requiring robust validation and explainability of algorithms. Data integrity and the absence of harmonized international guidelines limit widespread adoption, creating redundancy in submissions across global markets [73]. Moreover, ethical concerns surrounding algorithm transparency, potential bias and accountability must be addressed to ensure trust in AI-driven regulatory decisions.

Looking ahead, regulatory sandboxes and pilot programs are expected to accelerate safe AI adoption by allowing controlled testing of innovative digital solutions. The integration of AI into International Council for Harmonisation (ICH) guidelines could provide unified global standards for validation, quality control and data management, enabling more consistent acceptance of AI generated outcomes. The convergence of emerging technologies such as digital twins, blockchain and big data will further strengthen regulatory frameworks by enhancing predictive modelling, ensuring secure data handling and supporting real world evidence generation. Additionally, AI powered personalized medicine approvals hold promise to shift regulatory evaluation from traditional population based models to adaptive, precision driven pathways tailored to individual patient needs.

Beyond narrow AI the prospective evolution towards Artificial General Intelligence (AGI) and Artificial Superintelligence (ASI) presents a visionary horizon. AGI could autonomously integrate regulatory, clinical and scientific data for holistic decision making while ASI may surpass human cognition in modelling complex drug disease interactions and global harmonization challenges [84,85]. Although distant, preparing ethical and governance frameworks for AGI/ASI is critical to ensure safe integration into regulatory affairs practice.

In conclusion the convergence of AI pharmaceutical analytics and regulatory affairs practice represents a paradigm shift in modern drug approval. By embracing innovation while addressing regulatory, ethical and harmonization challenges, AI driven regulatory frameworks can evolve into transparent, globally harmonized and patient-centered ecosystems ultimately accelerating the delivery of safe and effective therapies worldwide.

Author Contributions

All authors contributed equally to this research. All authors read and approved the final manuscript.

Acknowledgements

We express our sincere thanks to the Department of Pharmaceutical chemistry, College of pharmacy, Madras Medical College (MMC), Chennai for providing necessary facilities for the research work.

Conflict of Interest

The authors declare no conflict of interest.

Funding

The authors did not receive any fundings from any private or government sources.

Ethical Approvals

This study does not involve experiments on animals or human subjects.

References

1. Gude S, et al. The synergy of artificial intelligence and machine learning in revolutionizing pharmaceutical regulatory affairs. Int J Pharm Sci Res. 2023;14(5):2001–10.
2. Rajani K, et al. Role of regulatory affairs in pharmaceutical company. Int J Pharm Res. 2022;14(4):1823–30.
3. Hussain HK, et al. Transforming healthcare: the rapid rise of artificial intelligence revolutionizing healthcare applications. Front Artif Intell. 2021;4:625078. doi:10.3389/frai.2021.625078.

4. Raza MA, et al. Artificial intelligence in pharmacy: an overview of innovations. J Pharm Innov. 2022;17(6):1502–15.
5. Lale S, et al. Role of drug regulatory affairs in pharma industry. World J Pharm Pharm Sci. 2021;10(5):1451–61.
6. Patel J, et al. Artificial intelligence in pharma industry – a rising concept. Int J Pharm Sci Rev Res. 2022;74(1):88–94.
7. Faculty of Medicine and Health, University of Sydney; Sanofi. Future directions in regulatory affairs. Regul Toxicol Pharmacol. 2022;133:105–18.
8. Oualikene-Gonin W, et al. Artificial intelligence integration in the drug lifecycle and in regulatory science: policy implications, challenges and opportunities. Front Med Technol. 2021;3:698415.
9. Prusty A, et al. The revolutionary role of artificial intelligence in pharmaceutical sciences. Indian J Pharm Educ Res. 2022;56(3):18–25.
10. Shelke S, et al. Navigating drug regulatory affairs: an analytical review of compliance in the pharmaceutical industry. Int J Pharm Chem Anal. 2022;9(2):58– 65.
11. Bohr A, et al. The rise of artificial intelligence in healthcare applications. Artif Intell Healthc. 2020;1(1):25–40.
12. Patel J, et al. Scope of artificial intelligence in the pharmaceutical field. Eur J Pharm Sci Rev. 2021;12(3):75–83.
13. Pathan I, et al. Revolutionizing pharmacology: AI-powered approaches in molecular modeling and ADMET prediction. J Pharm Pharmacol Res. 2024;12(3):112–30.
14. Kandhare P, et al. Artificial intelligence in pharmaceutical sciences: a comprehensive review. J Appl Pharm Sci 2023;13(2):45–58.
15. Tummala SR, et al. AI-driven predictive analytics for drug stability studies. Int J Pharm Sci Res. 2024;15(4):210–8. doi:10.5281/zenodo.11068492.
16. Generative AI in pharmaceutical research: accelerating drug discovery through predictive analytics and big data integration. Front Multidiscip Res J. 2023;4(2):27–33. doi:10.54660/IJFMR.2023.4.2.27-33.
17. Swanson K, et al. ADMET-AI: a machine learning ADMET platform for evaluation of large-scale chemical libraries. J Chem Inf Model. 2023;63(4):987–1002.
18. The future of drug discovery utilizing generative AI and big data analytics for accelerating pharmaceutical innovations. Nanotechnol Percept. 2018;14(3):120–35.
19. Gangwal A, et al. Artificial intelligence in natural product drug discovery: current applications and future perspectives. J Med Chem. 2025;68(7):3948–69.
20. Zhang Y, et al. Application of computational biology and artificial intelligence in drug design. Front Pharmacol. 2024;15:127–44.
21. Manepally A, et al. Applications and tools of artificial intelligence in analytical method development by HPLC. Int J Sci Res Arch. 2025;15(1):811–26. doi:10.30574/ijsra.2025.15.1.0969.
22. Lamberti MJ, et al. A study on the application and use of artificial intelligence to support drug development. Ther Innov Regul Sci. 2022;56(3):421–33.
23. Brown N, et al. Artificial intelligence in chemistry and drug design. J Cheminform. 2020;12:56.
24. Kaur S, et al, editors. Microbial metabolomics: recent developments, challenges and future opportunities. Singapore: Springer; 2023.
25. Mazzi F. Patentability of AI-generated inventions: a case study on pharma London: Queen Mary University of London; 2022.
26. Nene L, et al. Evolution of drug development and regulatory affairs: the demonstrated power of artificial intelligence. Pretoria: University of Pretoria & North-West University; 2023 [cited 2025 Aug 24].
27. Shivani E, et al. A review on essentials of regulatory affairs: drug approvals, compliance, and global regulations. Hyderabad: Gokaraju Rangaraju College of Pharmacy; 2022 [cited 2025 Aug 24].
28. DiFeo TJ. Safety and efficacy: the role of chemistry, manufacturing, and controls in pharmaceutical drug development. New Brunswick: Johnson & Johnson Pharmaceutical R&D; 2020 [cited 2025 Aug 24].
29. Kadam D, et al. Global regulatory harmonization for biosimilars: current progress, challenges, and future directions. Pune: Dattakal College of Pharmacy; 2022 [cited 2025 Aug 24].
30. Thippanna G, et al. A review on big data integration's difficulties with AI. Hyderabad: Ashoka Women's Engineering College; 2021 [cited 2025 Aug 24].
31. Makrani MF, et al. A comparative overview of global regulatory authorities: ensuring quality, safety, and efficacy in medicines. Udaipur: Bhupal Noble's College of Pharmacy; 2021 [cited 2025 Aug 24].
32. Wahid R, et al. Chemistry, manufacturing and control (CMC) and clinical trial technical support for influenza vaccine manufacturers. Vaccine. 2019;37(30):4429– 36.

33. Shukla D, et al. Role of artificial intelligence in pharmacovigilance. Int J Pharm Sci Res. 2021;12(7):1000–7.
34. Venna SR. AI and automation in regulatory operations: the future of eCTD submissions. Regul Focus. 2021;26(4):55–61.
35. Ghoshal R. Establishing global ethical standards for AI: a roadmap for regulatory harmonization. J Law Policy. 2022;15(2):77–89.
36. Hauben M. Artificial intelligence and data mining for the pharmacovigilance of drug–drug interactions. Drug Saf. 2020;43(10):939–48.
37. Reddy S. Global harmonization of artificial intelligence-enabled software as a medical device regulation: addressing challenges and unifying standards. Front Digit Health. 2021;3:658880.
38. Dimitsaki S, et al. Applying artificial intelligence in structured real-world data for pharmacovigilance purposes: a systematic literature review. J Med Internet Res. 2024;26:e56789.
39. Venna SR. Regulatory operations in the digital age: optimizing eCTD workflows with data analytics. Regul Rapporteur. 2022;19(6):15–22.
40. Venna SR. Optimising global eCTD submissions: harmonisation challenges and solutions. Pharm Regul Aff. 2023;12(1):33–40.
41. Singh B, et al. Pharmaceutical advances: integrating artificial intelligence in QSAR, combinatorial and green chemistry practices. Dublin: TU Dublin; 2023 [cited 2025 Aug 24].
42. Cronin MTD, et al. Making in silico predictive models for toxicology FAIR. Liverpool: Liverpool John Moores University; 2022 [cited 2025 Aug 24].
43. Pérez Santín E, et al. Toxicity prediction based on artificial intelligence: a multidisciplinary overview. 2022 [cited 2025 Aug 24].
44. Anonymous. Artificial intelligence and green chemistry: high-impact synergies between green chemistry fields and artificial intelligence. 2022 [cited 2025 Aug 24].
45. Duran-Frigola M, et al. Advancing targeted protein degradation via multiomics profiling and artificial intelligence 2022 [cited 2025 Aug 24].
46. Anonymous. Which modern AI methods provide accurate predictions of toxicological end points? Analysis of Tox24 challenge results 2022 [cited 2025 Aug 24].
47. Lin Z, et al. Machine learning and artificial intelligence in toxicological sciences. Gainesville: University of Florida; 2023 [cited 2025 Aug 24].
48. Grigoryan A, et al. Smart formulation: AI-driven web platform for optimization and stability prediction of compounded pharmaceuticals using KNIME. 2025 [cited 2025 Aug 24].
49. Kurul F, et al. Principles of green chemistry: building a sustainable future. 2025 [cited 2025 Aug 24].
50. Mehta GU. Accelerated approval is not conditional approval: insights from international expedited approval programs. FDA Center for Drug Evaluation and Research; 2023.
51. Desai A, et al. What is reproducibility in artificial intelligence and machine learning research 2023 [cited 2025 Aug 24].
52. Chang L, et al. AI-driven synthetic biology for non-small cell lung cancer drug effectiveness-cost analysis in intelligent assisted medical systems. IEEE J Biomed Health Inform. 2022;26(10):5055–66.
53. Ajami RA, et al. Artificial intelligence: opportunities and challenges. J Asia Pac Bus. 2023;24(2):73–5. doi:10.1080/10599231.2023.2210239.
54. De Micco F, et al. Artificial intelligence in healthcare: transforming patient safety with intelligent systems—a systematic review . 2023 [cited 2025 Aug 24].
55. Prakash S, et al. From burden to advantage: leveraging AI/ML for regulatory reporting in US banking. RBC Capital Markets; 2023.
56. Industry experiences of artificial intelligence: benefits and challenges in operations and supply chain management. Prod Plan Control. 2021;33(16):1–13. doi:10.1080/09537287.2021.1882695.
57. Yu B. After computational reproducibility: scientific reproducibility and trustworthy AI. Univ California Berkeley; 2024 May 24. doi:10.1162/99608f92.ea5e6f9a.
58. Alhosani K, et al. Opportunities, challenges, and benefits of AI innovation in government services: a review. 2024 [cited 2025 Aug 24].
59. Wong W, et al. The value of the accelerated approval pathway: real-world outcomes associated with reducing the time between innovations. Future Oncol. 2024;20(16):1099–110. doi:10.2217/fon-2023-0514.
60. Transforming pharmaceutical R&D with AI technologies 2025 Jun [cited 2025 Aug 24].
61. European Medicines Agency. Regulatory sandboxes: fostering innovation in medicines development London: EMA; 2023 [cited 2025 Aug 24]. https://www.ema.europa.eu/
62. U.S. Food and Drug Administration. Artificial intelligence/machine learning (AI/ML)-based software as a medical device (SaMD) action plan. Silver Spring: FDA; 2021 [cited 2025 Aug 24]. https://www.fda.gov/

63. International Council for Harmonisation. Reflection paper on artificial intelligence in medicines regulation. ICH; 2022 [cited 2025 Aug 24]. https://www.ich.org/
64. Bruynseels K, et al. Digital twins in health care: ethical implications of an emerging engineering paradigm. Front Genet. 2018;9:31. doi:10.3389/fgene.2018.00031.
65. Agbo CC, et al. Blockchain technology in healthcare: a comprehensive review and directions for future research. Appl Sci. 2019;9(9):1736. doi:10.3390/app9091736.
66. Wang L, et al. Big data in medical applications and regulatory science: opportunities and challenges. Health Inf Sci Syst. 2020;8(1):20. doi:10.1007/s13755-020-00103- 8.
67. Schork NJ. Personalized medicine: time for one-person trials. Nature. 2015;520(7549):609–11. doi:10.1038/520609a.
68. U.S. National Academies of Sciences, Engineering, and Medicine. Realizing the promise of personalized medicine with AI and data science. Washington (DC): National Academies Press; 2022.
69. Tzoulaki I, et al. Worldwide exposures to AI-driven health technologies: towards a smart regulatory ecosystem. Lancet Digit Health. 2021;3(11):e684–96. doi:10.1016/S2589-7500(21)00170-1.
70. Cheng L, Gong X. Appraising regulatory framework towards artificial general intelligence (AGI) under digital humanism. Int J Digit Law Gov. 2024;1(2):269–312.Available from: https://doi.org/10.1515/ijdlg-2024-0015 De Gruyter Brill
71. Bostrom N, Dafoe A, Flynn C. Public policy and superintelligent AI: a vector field approach. In: Liao SM, editor. Ethics of Artificial Intelligence. Oxford: Oxford University Press; 2020. Chapter available from: https://www.nickbostrom.com/papers/aipolicy.pdf
72. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463-77. doi:10.1038/s41573-019-0024-5.
73. Beam AL, Kohane IS. Big data and machine learning in health care. JAMA. 2018;319(13):1317-8. doi:10.1001/jama.2017.18391.
74. Schneider G. Automating drug discovery. Nat Rev Drug Discov. 2018;17(2):97-113. doi:10.1038/nrd.2017.232.